Abstract
Results For the SRWG whole blood panel, all six XMRV negative samples were assay negative, while all the 22Rv1-spiked samples from 0.5 cells/mL to 9,900 cells/mL were detected (3/3 for each panel member). For the SRWG plasma panel, all six XMRV negative samples were assay negative, while the 22Rv1 supernatant-spiked plasma samples were detected as positive, 1/3 for the 3.2 XMRV copies/mL panel member, 2/3 for the 16 copies/mL panel member, and 3/3 for panel members containing > 80 copies/mL. For screening of clinical specimen, assay positive results were obtained for 10% (2/20) of prostate cancer FFPE specimens, 0.5% (2/400) of prostate cancer urine pellets, and 0% (0/135) of the cervical swab specimens.
Highlights
Xenotropic murine leukemia virus-related virus (XMRV) has been reported to be associated with prostate cancer and chronic fatigue syndrome
A prototype RT-PCR assay for detection of XMRV in multiple human sample types
Assay performance was assessed by testing two blinded panels prepared by the Blood XMRV Scientific Research Working Group (SRWG), as well as clinical specimens
Summary
Xenotropic murine leukemia virus-related virus (XMRV) has been reported to be associated with prostate cancer and chronic fatigue syndrome. To help resolve the role of XMRV in human disease, it is critical to develop sensitive and accurate PCR assays for XMRV detection
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
